Genscript Biotech Corporation convened its Annual General Meeting on 5 June 2026, during which all resolutions were approved by poll, confirming broad shareholder support for the group’s strategic and governance agenda.

Key Approvals 1. FY 2025 Results: The audited consolidated financial statements and accompanying reports for the year ended 31 December 2025 were adopted with 99.95% of votes cast in favour (1.23 billion shares).

2. Board Composition and Remuneration: • Executive Directors Dr. Frank Zhang, Mr. Robin Meng, Dr. Li Zhu and independent non-executive director Dr. Victor Shi were re-elected, attracting affirmative votes ranging from 96.32% to 99.82%. • Authorisation for the Board to fix director remuneration passed with 99.98% support.

3. Auditor: Ernst & Young was re-appointed as external auditor, with 99.91% approval, and the Board was authorised to determine its fees.

4. Share Mandates: • General mandate to issue new shares—up to 20% of issued share capital—was backed by 87.88% of votes. • Authority to repurchase up to 10% of issued shares received 99.99% approval. • The extension mandate, allowing addition of repurchased shares to the issuance limit, secured 88.18% support.

5. Memorandum & Articles Update: Shareholders endorsed amendments to the company’s constitutional documents with 99.00% approval, bringing the fifth amended and restated memorandum and articles into immediate effect.

Voting Mechanics • Shares in issue: 2.19 billion. • Shares carrying voting rights at the meeting: 1.23 billion, after excluding 3.61 million unvested RSU shares (0.16% of issued capital) that abstained from voting. • The scrutineer for vote tabulation was Computershare Hong Kong Investor Services Limited.

All directors attended the meeting in person or via telecommunication. The passage of every resolution consolidates Genscript Biotech’s governance framework and provides flexibility for potential capital management initiatives during the coming year.